Robust and inducible genome editing via an all-in-one prime editor in human pluripotent stem cells
Prime editing (PE) allows for precise genome editing in human pluripotent stem cells (hPSCs), such as introducing single nucleotide modifications, small insertions or deletions at a specific genomic locus. Here, we systematically compare a panel of prime editing conditions in hPSCs and generate a potent prime editor, "PE-Plus", through co-inhibition of mismatch repair and p53-mediated cellular stress responses. We further establish an inducible prime editing platform in hPSCs by incorporating the PE-Plus into a safe-harbor locus and demonstrated temporal control of precise editing in both hPSCs and differentiated cells. By evaluating disease-associated mutations, we show that this platform allows efficient creation of both monoallelic and biallelic disease-relevant mutations in hPSCs. In addition, this platform enables the efficient introduction of single or multiple edits in one step, demonstrating potential for multiplex editing. Our method presents an efficient and controllable multiplex prime editing tool in hPSCs and their differentiated progeny.
Authors
- Aaron Zhong (ORCID: https://orcid.org/0000-0002-2468-0923)
- Bernny Ramirez
- Ting Zhou (ORCID: https://orcid.org/0000-0003-1423-1507)
- Lorenz Studer (ORCID: https://orcid.org/0000-0003-0741-7987)
- Mega Sidharta
- Benjamin Persily (ORCID: https://orcid.org/0009-0001-3033-7232)
- Tae Wan Kim (ORCID: https://orcid.org/0000-0002-0831-6881)
- Youjun Wu (ORCID: https://orcid.org/0000-0002-3557-1159)
Institutions
- Kettering University (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1038/s41467-024-55104-1
- Citations
- 8
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- Memorial Sloan-Kettering Cancer Center
- New York State Stem Cell Science
- Cycle for Survival
- National Institutes of Health
- Weill Cornell Medical College
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- National Cancer Institute